A Study of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS)

Completed · Phase 2

Conditions studied: Complex Regional Pain Syndrome (RSD)

In brief

This is a multicenter, open-label study in adult subjects with Type 1 Complex Regional Pain Syndrome. Subjects diagnosed with unilateral Type 1 CRPS will be enrolled sequentially to receive CC-5013 10 mg/day orally. For each subject the study consists of two phases: Pre-treatment phase(1 wk) and treatment phase (12 wks)

Key facts

Study ID

NCT00067743

Run by

Celgene Corporation

People needed

40

Starts

2003-08-01

Expected to finish

2007-08-01

Last updated by the study team

2008-01-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• A diagnosis of Type 1 CRPS as defined by modified International Association for the Study of Pain criteria (App 1) for at least one year duration
• Unilateral involvement of a distal hand or foot with or without proximal speed must be present. The most severely affected limb will be designated the index limb.
• CRPS pain severity score in the index limb of 4 or greater on an 11-point (0-10) NRS (Appendix I).
• Opioid analgesics, non-opioid analgesics, non-steroidal anti-inflammatory drugs, anticonvulsants and antidepressant drugs may be continued provided that the subject was on stable doses for at least four weeks prior to the Treatment phase.
• Understand and voluntarily sign an informed consent form
• Able to adhere to the study visit schedule and other protocol requirements
• Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy test within 7 days of starting study drug.
• In addition, sexually active WCBP must agree to use adequate contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) while on study drug.
• WCBP must agree to have pregnancy tests every 4 weeks while on study drug.
• The average CRPS pain severity score in the index limb at the end of the Pre-Treatment Phase I (must be 4 or greater) and 2 each of the daily scores over the week must be within +/- one point of this average.

You may not qualify if…

• Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
• Prior treatment with CC-5013
• Prior development of an allergic reaction/hypersensitivity while taking thalidomide.
• Prior development of a moderate or sever rash or any desquamation while taking thalidomide.
• Pregnant or lactating females.
• Active litigation, compensation or disability issues related to CRPS.
• Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
• Use of any other experimental drug or therapy within 28 days of the treatment phase.

Where it is running

• UCSD Center for Pain and Palliative Medicine — La Jolla, California, United States
• Johns Hopkins Hospital — Baltimore, Maryland, United States
• UNC Hospitals University of North Carolina — Chapel Hill, North Carolina, United States
• The Center for Clinical Research — Winston-Salem, North Carolina, United States
• Drexel University College of Medicine — Philadelphia, Pennsylvania, United States
• Swedish Pain Management — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.